



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

Our STN: BL 103951/5170

MAR 07 2008

Amgen, Incorporated
Attention: Lisa Shamon-Taylor, Ph.D.
Senior Manager, Regulatory Affairs
One Amgen Center Drive
Thousand Oaks, CA 91320

Dear Dr. Shamon-Taylor:

Your request to supplement your biologics license application for darbepoetin alfa (Aranesp) to revise the Boxed Warnings and the Warnings section of the package insert to include information from the PREPARE/DE-2001-0033 study utilizing darbepoetin alfa and the GOG191 study utilizing epoetin alfa has been approved.

We also refer to STN BL 103951 [redacted] which contains an interim clinical study report and interim datasets for study DE-2001-0033 (PREPARE). We also refer to BL 103234/5164 for information regarding study GOG 191.

We acknowledge the statement in your February 29, 2008, letter that you will post a copy of the Dear Healthcare Provider Letter (DHCP) within 72 hours of receipt of this letter. In addition, we acknowledge your agreement to distribute the Dear Healthcare Provider Letter with the attached revised labeling within ten days from this approval (March 17, 2008).

Pursuant to 21 CFR 201.57(c)(18) and 201.80(f)(2), patient labeling must be reprinted immediately following the last section of labeling or, alternatively, accompany the prescription drug labeling.


Within 21 days of the date of this letter, submit content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/oc/datacouncil/spl.html>, that is identical in content to the enclosed labeling text. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission "Product Correspondence – Final SPL for approved STN BL 103951/5170." In addition, within 21 days of the date of this letter, amend any pending supplement(s) for this BLA with content of labeling in SPL format to include the changes approved in this supplement.

Marketing the product with labeling that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please refer to <http://www.fda.gov/cder/biologics/default.htm> for information regarding therapeutic biological products, including the addresses for submissions.

This information will be included in your biologics license application file.

Sincerely,



Patricia Keegan, M.D.

Director

Division of Biologic Oncology Products

Office of Oncology Drug Products

Center for Drug Evaluation and Research

Enclosure: Package Insert
Patient Package Insert Labeling